Two summaries have recently appeared in the technical press, discussing the surprising results after 5 years of followup from a randomized trial involving Ibrutinib + Rituximab vs. placebo + Rituximab. The surprise is not that the drug combination provides superior numbers. The surprise is that the combination apparently acts independently of the patient’s mutation status, unlike Ibrutinib alone.
The data were presented at the recent American Society of Hematology (ASH) annual meeting.
See the coverage in CureToday:
Or in Targeted Oncology: